Marker Therapeutics is trading at $1.12, up 7.50% on October 19, 2026, after receiving a $2.6 million FDA grant for its MT-601 Phase 1 study. - The non-dilutive funding follows selection through the FDA’s competitive Orphan Products Clinical Trials program. - The study will evaluate MT-601 in locally advanced, unresectable pancreatic cancer; Marker anticipates starting it in Q1 2027. - Shares rose 13.04% on October 16; no reliable live volume figure was available.